FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Edward Berger

Research Profile

Living Beings

Chemicals & Drugs

Physiology

Anatomy

Disorders

HIV Infections

Co-author Network

Publications

TOP 3
Yingyun Cai; Edward A Berger
An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.
Miriam Triyatni; Edward A Berger; Bertrand Saunier
A new model to produce infectious hepatitis C virus without the replication requirement.
Edward A Berger
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Edward Berger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Yingyun Cai; Edward A Berger
An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.
Antiviral research 2011;90(3):143-50.
2011: Miriam Triyatni; Edward A Berger; Bertrand Saunier
A new model to produce infectious hepatitis C virus without the replication requirement.
PLoS pathogens 2011;7(4):e1001333.
2011: Edward A Berger
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.
Current opinion in HIV and AIDS 2011;6(1):80-5.
2010: Edward A Berger; Ira Pastan
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.
PLoS pathogens 2010;6(6):e1000803.
2010: Laurel A Lagenaur; Vadim A Villarroel; Virgilio Bundoc; Barna Dey; Edward A Berger
sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.
Retrovirology 2010;7():11.
2009: Karl Salzwedel; Edward A Berger
Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer.
Retrovirology 2009;6():75.
2007: Edward A Berger; Ghalib Alkhatib
HIV gp120 interactions with coreceptors: insights from studies with CCR5-based peptides.
European journal of medical research 2007;12(9):403-7.
2007: Ghalib Alkhatib; Edward A Berger
HIV coreceptors: from discovery and designation to new paradigms and promise.
European journal of medical research 2007;12(9):375-84.
2006: Paul E Kennedy; Tapan K Bera; Qing-Cheng Wang; Maria Gallo; Wendeline Wagner; Mark G Lewis; Edward A Berger; Ira Pastan
Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.
Journal of leukocyte biology 2006;80(5):1175-82.
2006: Johnan A R Kaleeba; Edward A Berger
Broad target cell selectivity of Kaposi's sarcoma-associated herpesvirus glycoprotein-mediated cell fusion and virion entry.
Virology 2006;354(1):7-14.
2006: Johnan A R Kaleeba; Edward A Berger
Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT.
Science (New York, N.Y.) 2006;311(5769):1921-4.
2005: Riccardo Cassiani Ingoni; Heather L Greenstone; Donatella Donati; Anna Fogdell-Hahn; Elena Martinelli; Daniel Refai; Roland Martin; Edward A Berger; Steven Jacobson
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion.
Glia 2005;52(3):252-8.
2005: Laurel A Lagenaur; Edward A Berger
An anti-HIV microbicide comes alive.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(35):12294-5.
2005: Paolo Lusso; Patricia L Earl; Francesca Sironi; Fabio Santoro; Chiara Ripamonti; Gabriella Scarlatti; Renato Longhi; Edward A Berger; Samuele E Burastero
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Journal of virology 2005;79(11):6957-68.
2004: Lokesh Agrawal; Zainab Vanhorn-Ali; Edward A Berger; Ghalib Alkhatib
Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.
Blood 2004;103(4):1211-7.
2003: David G Brooks; Dean H Hamer; Philip A Arlen; Lianying Gao; Gregory Bristol; Christina Kitchen; Edward A Berger; Jerome A Zack
Molecular characterization, reactivation, and depletion of latent HIV.
Immunity 2003;19(3):413-23.
2003: Fabio Santoro; Heather L Greenstone; Alessandra Insinga; M Kathryn Liszewski; John P Atkinson; Paolo Lusso; Edward A Berger
Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46.
The Journal of biological chemistry 2003;278(28):25964-9.
2003: Barna Dey; Edward A Berger
Vaccinia-based reporter gene cell-fusion assays to quantitate functional interactions of HIV envelope glycoprotein with receptors.
Current protocols in immunology / edited by John E. Coligan ... [et al.] 2003;Chapter 12():Unit 12.10.
2003: Barna Dey; Christie S Del Castillo; Edward A Berger
Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
Journal of virology 2003;77(5):2859-65.
2002: Heather L Greenstone; Fabio Santoro; Paolo Lusso; Edward A Berger
Human Herpesvirus 6 and Measles Virus Employ Distinct CD46 Domains for Receptor Function.
The Journal of biological chemistry 2002;277(42):39112-8.
2002: Louise McHugh; Stella Hu; B K Lee; Kenneth Santora; Paul E Kennedy; Edward A Berger; Ira Pastan; Dean H Hamer
Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis.
The Journal of biological chemistry 2002;277(37):34383-90.
2001: Marco L Schito; Paul E Kennedy; R P Kowal; Edward A Berger; Alan Sher
A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression.
The Journal of infectious diseases 2001;183(11):1592-600.
2000: David H McDermott; J S Colla; CA Kleeberger; M Plankey; P S Rosenberg; ED Smith; Peter Zimmerman; Christophe Combadière; Susan F Leitman; Richard A Kaslow; J J Goedert; Edward A Berger; Thomas R O'Brien; Philip M Murphy
Genetic polymorphism in CX3CR1 and risk of HIV disease.
Science (New York, N.Y.) 2000;290(5499):2031.
2000: K Salzwedel; Edward A Berger
Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(23):12794-9.
2000: Barna Dey; Deborah L Lerner; Paolo Lusso; M R Boyd; John H Elder; Edward A Berger
Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Journal of virology 2000;74(10):4562-9.
2000: Harris Goldstein; Massimo Pettoello-Mantovani; T K Bera; Ira Pastan; Edward A Berger
Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice.
The Journal of infectious diseases 2000;181(3):921-6.
2000: K Salzwedel; ED Smith; Barna Dey; Edward A Berger
Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.
Journal of virology 2000;74(1):326-33.
1999: Fabio Santoro; Paul E Kennedy; Giuseppe Locatelli; Mauro S Malnati; Edward A Berger; Paolo Lusso
CD46 is a cellular receptor for human herpesvirus 6.
Cell 1999;99(7):817-27.
1999: MARK ESSER; T Mori; I Mondor; Quentin J Sattentau; Barna Dey; Edward A Berger; M R Boyd; Jeffrey D Lifson
Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Journal of virology 1999;73(5):4360-71.
1999: Edward A Berger; P M Murphy; Joshua M Farber
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
Annual review of immunology 1999;17():657-700.
1998: Edward A Berger; Bernard Moss; Ira Pastan
Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(20):11511-3.
1998: Christophe Combadiere; K Salzwedel; ED Smith; HL Tiffany; Edward A Berger; Philip M Murphy
Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.
The Journal of biological chemistry 1998;273(37):23799-804.
1998: Tapan K Bera; Paul E Kennedy; Edward A Berger; C F Barbas; Ira Pastan
Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
Molecular medicine (Cambridge, Mass.) 1998;4(6):384-91.
1998: Edward A Berger
Introduction: HIV co-receptors solve old questions and raise many new ones.
Seminars in immunology 1998;10(3):165-8.
1998: H A Bazan; Ghalib Alkhatib; Christopher C Broder; Edward A Berger
Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates.
Journal of virology 1998;72(5):4485-91.
1998: HL Tiffany; Ghalib Alkhatib; Christophe Combadiere; Edward A Berger; Philip M Murphy
CC chemokine receptors 1 and 3 are differentially regulated by IL-5 during maturation of eosinophilic HL-60 cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(3):1385-92.
1998: Edward A Berger; R W Doms; E M Fenyö; B T Korber; Dan R Littman; J P Moore; Quentin J Sattentau; H Schuitemaker; Joseph Sodroski; R A Weiss
A new classification for HIV-1.
Nature 1998;391(6664):240.
1998: Edward A Berger
HIV entry and tropism. When one receptor is not enough.
Advances in experimental medicine and biology 1998;452():151-7.
1997: Ghalib Alkhatib; Edward A Berger; Philip M Murphy; J E Pease
Determinants of HIV-1 coreceptor function on CC chemokine receptor 3. Importance of both extracellular and transmembrane/cytoplasmic regions.
The Journal of biological chemistry 1997;272(33):20420-6.
1997: Ghalib Alkhatib; Seema Ahuja; D Light; Srinivas Mummidi; Edward A Berger; Sunil Ahuja
CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion.
The Journal of biological chemistry 1997;272(32):19771-6.
1997: Ghalib Alkhatib; M Locati; Paul E Kennedy; Philip M Murphy; Edward A Berger
HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Virology 1997;234(2):340-8.
1997: Ghalib Alkhatib; Fang Liao; Edward A Berger; Joshua M Farber; Keith W C Peden
A new SIV co-receptor, STRL33.
Nature 1997;388(6639):238.
1997: Fang Liao; Ghalib Alkhatib; Keith W C Peden; G Sharma; Edward A Berger; Joshua M Farber
STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.
The Journal of experimental medicine 1997;185(11):2015-23.
1997: Edward A Berger
HIV entry and tropism: the chemokine receptor connection.
AIDS (London, England) 1997;11 Suppl A():S3-16.
1997: Peter Zimmerman; A Buckler-White; Ghalib Alkhatib; T Spalding; Joseph Kubofcik; Christophe Combadiere; Drew Weissman; OJ Cohen; A Rubbert; G Lam; M Vaccarezza; Paul E Kennedy; Vasanthapuram Kumaraswami; J V Giorgi; Roger Detels; J Hunter; M Chopek; Edward A Berger; Anthony Fauci; Thomas B Nutman; Philip M Murphy
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.
Molecular medicine (Cambridge, Mass.) 1997;3(1):23-36.
1996: Ghalib Alkhatib; Christopher C Broder; Edward A Berger
Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages.
Journal of virology 1996;70(8):5487-94.
1996: Ghalib Alkhatib; Christophe Combadiere; Christopher C Broder; Y Feng; Paul E Kennedy; Philip M Murphy; Edward A Berger
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science (New York, N.Y.) 1996;272(5270):1955-8.
1996: Y Feng; Christopher C Broder; Paul E Kennedy; Edward A Berger
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science (New York, N.Y.) 1996;272(5263):872-7.
1995: Christopher C Broder; Edward A Berger
Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(19):9004-8.
1995: O Nussbaum; Christopher C Broder; Bernard Moss; L B Stern; S Rozenblatt; Edward A Berger
Functional and structural interactions between measles virus hemagglutinin and CD46.
Journal of virology 1995;69(6):3341-9.
1994: O Nussbaum; Christopher C Broder; Edward A Berger
Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.
Journal of virology 1994;68(9):5411-22.
1994: Christopher C Broder; O Nussbaum; W G Gutheil; W W Bachovchin; Edward A Berger
CD26 antigen and HIV fusion?
Science (New York, N.Y.) 1994;264(5162):1156-9; author reply 1162-5.
1994: Christopher C Broder; Paul E Kennedy; F Michaels; Edward A Berger
Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors.
Gene 1994;142(2):167-74.
1993: Christopher C Broder; Dimiter S Dimitrov; R Blumenthal; Edward A Berger
The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s).
Virology 1993;193(1):483-91.
1993: Dimiter S Dimitrov; Christopher C Broder; Edward A Berger; Robert Blumenthal
Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction.
Journal of virology 1993;67(3):1647-52.
1993: Christopher C Broder; Edward A Berger
CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.
Journal of virology 1993;67(2):913-26.
1993: Paul E Kennedy; Bernard Moss; Edward A Berger
Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin.
Virology 1993;192(1):375-9.
1993: P Ashorn; Edward A Berger; Bernard Moss
Vaccinia virus vectors for study of membrane fusion mediated by human immunodeficiency virus envelope glycoprotein and CD4.
Methods in enzymology 1993;221():12-8.
1992: Edward A Berger; J R Sisler; Patricia L Earl
Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.
Journal of virology 1992;66(10):6208-12.
1992: P Ashorn; Bernard Moss; Edward A Berger
Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins.
Journal of acquired immune deficiency syndromes 1992;5(1):70-7.
1992: P Ashorn; Bernard Moss; Edward A Berger
Therapeutic strategies employing CD4, the HIV receptor.
Advances in experimental medicine and biology 1992;312():71-81.
1991: Edward A Berger; Jeffrey D Lifson; L E Eiden
Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(18):8082-6.
1991: P Ashorn; G Englund; Malcolm Martin; Bernard Moss; Edward A Berger
Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages.
The Journal of infectious diseases 1991;163(4):703-9.
1990: P Ashorn; Bernard Moss; John N Weinstein; V K Chaudhary; David J FitzGerald; Ira Pastan; Edward A Berger
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(22):8889-93.
1990: Edward A Berger; V K Chaudhary; K A Clouse; D Jaraquemada; J A Nicholas; K L Rubino; D J Fitzgerald; Ira Pastan; Bernard Moss
Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions.
AIDS research and human retroviruses 1990;6(6):795-804.
1990: P A Ashorn; Edward A Berger; Bernard Moss
Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells.
Journal of virology 1990;64(5):2149-56.
1990: P Ashorn; Bernard Moss; Edward A Berger
Anti-HIV effects of CD4-Pseudomonas exotoxin on human lymphocyte and monocyte/macrophage cell lines.
Annals of the New York Academy of Sciences 1990;616():149-54.
1989: Edward A Berger; K A Clouse; V K Chaudhary; S Chakrabarti; D J FitzGerald; Ira Pastan; Bernard Moss
CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(23):9539-43.
1988: T Mizukami; Thomas R Fuerst; Edward A Berger; Bernard Moss
Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(23):9273-7.
1988: V K Chaudhary; T Mizukami; Thomas R Fuerst; David J FitzGerald; Bernard Moss; Ira Pastan; Edward A Berger
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.
Nature 1988;335(6188):369-72.
1988: Edward A Berger; Thomas R Fuerst; Bernard Moss
A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(7):2357-61.